Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Home
/
update
/
details

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

NextEdge Admin

12 Nov 2024

1 min 43 sec

Biocytogen Pharmaceuticals , a global biotech company specializing in antibody and ADC therapeutic discovery, announced that IDEAYA Biosciences , focused on precision oncology, has secured an exclusive worldwide license for Biocytogen’s B7H3/PTK7 bispecific ADC (BsADC) program, IDE034, and designated it as a development candidate.

Dr. Yuelei Shen, CEO of Biocytogen, expressed enthusiasm for IDEAYA’s decision to license IDE034, which incorporates Biocytogen’s proprietary topoisomerase linker-payload, noting it as a validation of the RenLite® platform and a promising step toward treatments for solid tumors. IDEAYA’s CSO, Dr. Michael White, highlighted IDE034's potential as a first-in-class B7H3/PTK7 topo-I-payload BsADC, demonstrating significant tumor regression in preclinical models, particularly in lung, colorectal, and head and neck cancers. IDE034 may be used as a monotherapy or combined with IDEAYA's PARG inhibitor, IDE161.

IDEAYA aims for an IND submission to the FDA in 2025 for IDE034, following the completion of preclinical studies. Under the licensing agreement, Biocytogen will receive up to $406.5 million in fees, including up to $100 million in milestone payments, plus royalties on net sales.